TransCode Therapeutics Announces Prolonged Survival In Murine Models With Glioblastoma Treated With Its Lead Candidate, TTX-MC138
Portfolio Pulse from Benzinga Newsdesk
TransCode Therapeutics, Inc. (NASDAQ:RNAZ) announced improved survival in murine models bearing human glioblastoma multiforme (GBM) tumors treated with its lead therapeutic candidate, TTX-MC138. The study showed that mice treated with TTX-MC138 survived significantly longer than those in the control group. TransCode believes that TTX-MC138 could be an alternative treatment in cases where resistance to standard-of-care chemotherapy has occurred. The company is enrolling patients in a first-in-human clinical trial with TTX-MC138 in patients with advanced solid cancers.
October 26, 2023 | 12:20 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
TransCode Therapeutics' lead therapeutic candidate, TTX-MC138, showed promising results in treating GBM tumors in murine models. The company is enrolling patients in a first-in-human clinical trial with TTX-MC138 in patients with advanced solid cancers.
The news of improved survival in murine models treated with TransCode's lead therapeutic candidate, TTX-MC138, is positive for the company. This could potentially lead to increased investor confidence and a positive impact on the company's stock price in the short term. The initiation of a first-in-human clinical trial also indicates progress in the company's product pipeline, which could further boost investor sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100